Press release
Esophageal Cancer Pipeline 2024 | BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company
Discover the latest drugs and treatment options in the Esophageal Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Esophageal Cancer Pipeline Outlook [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Esophageal Cancer Pipeline Report
* July 2024:- AstraZeneca- A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors.
* July 2024;- Seagen- A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers. This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX). It will look at what side effects happen when participants take this combination of drugs.
* DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.
* The leading Esophageal Cancer Companies working in the market include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
* Promising Esophageal Cancer Therapies in the various stages of development include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Stay ahead with the most recent pipeline outlook for Esophageal Cancer. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Esophageal Cancer Treatment [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Emerging Drugs Profile
* AN-0025: Adlai Nortye
AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
* Tucatinib: Seagen
Tucatinib (TUKYSA Registered ) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.
* APX 005M: Apexigen
APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.
Explore groundbreaking therapies and clinical trials in the Esophageal Cancer Pipeline. Access DelveInsight's detailed report now! @ New Esophageal Cancer Drugs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Esophageal Cancer Companies
BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Esophageal Cancer Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Esophageal Cancer Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Esophageal Cancer Market Drivers and Barriers [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Esophageal Cancer Pipeline Report
* Coverage- Global
* Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.
* Esophageal Cancer Therapies-Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.
Get the latest on Esophageal Cancer Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Esophageal Cancer Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Esophageal Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Esophageal Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Last Stage Products (Phase II/III)
* Tucatinib: Seagen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* APX 005M: Apexigen
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Esophageal Cancer Key Companies
* Esophageal Cancer Key Products
* Esophageal Cancer - Unmet Needs
* Esophageal Cancer - Market Drivers and Barriers
* Esophageal Cancer - Future Perspectives and Conclusion
* Esophageal Cancer Analyst Views
* Esophageal Cancer Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-pipeline-2024-beigene-astrazeneca-cspc-zhongqi-pharmaceutical-technology-amgen-jiangsu-hengrui-medicine-oncolys-biopharma-pfizer-novartis-luye-pharma-eli-lilly-and-company]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Esophageal Cancer Pipeline 2024 | BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company here
News-ID: 3571085 • Views: …
More Releases from ABNewswire
Oral Surgeon Huntington Beach Practice Elevates Standards for Patient Comfort an …
Huntington Beach oral surgery practice, The Wisdom Teeth Guru sets new patient care standards through specialized training, advanced sedation options, and efficient same-day treatment capabilities under Dr. Kiet Tran's leadership.
A Huntington Beach dental practice has gained recognition for transforming how patients experience oral surgery procedures. The Wisdom Teeth Guru [https://www.google.com/maps/place/The+Wisdom+Teeth+Guru/data=!4m2!3m1!1s0x0:0x98592ab69d239d3a?sa=X&ved=1t:2428&hl=en&ictx=111], led by Dr. Kiet Tran, has established new benchmarks in patient care through advanced techniques and a commitment to making…
Columbus Moving Services Expands as Moving Ahead Services Responds to Central Oh …
Moving Ahead Services expands coverage across 23 Central Ohio communities, offering flexible moving solutions with regulatory compliance and community partnerships that support both residential and commercial relocations.
The Central Ohio region continues to experience steady population growth, and Moving Ahead Services has positioned itself to address the increasing demand for professional relocation assistance. The expansion of Columbus moving services reflects the company's two decades of experience serving the area, with operations…
What Does a Full-Service Move Include? Moving Companies Report Surge in Demand f …
Greenville homeowners increasingly prefer comprehensive relocation packages that handle packing, furniture assembly, transportation, and setup. Professional services reduce stress and damage while streamlining transitions.
Homeowners and renters across Greenville are opting for comprehensive relocation packages as the complexity of modern moves continues to grow. Recent trends show that families and businesses alike are seeking moving companies for an end-to-end solution that eliminates the stress traditionally associated with changing addresses. This shift…
Local Garage Door Company Sees Surge in Emergency Repairs Following Extreme Temp …
AA Garage Door LLC reports increased emergency repairs across St. Paul as extreme cold causes cable failures and spring breaks. Technicians respond to urgent service needs throughout Twin Cities neighborhoods affected by harsh winter conditions.
Recent weather patterns across the St. Paul region have created unprecedented challenges for homeowners, with plummeting temperatures causing significant strain on residential overhead door systems. AA Garage Door LLC, a trusted garage door company [https://maps.google.com/maps?ll=44.91738,-93.190993&z=16&t=h&hl=en&gl=PH&mapclient=embed&cid=15111651982362415047&q=garage+door+company&oq=garage+door+company+near+me] serving…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
